Axsome's Sunosi comes up short in trial but shows promise in treating MDD with daytime sleepiness
A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity disorder, Axsome Therapeutics has unveiled mixed results for the same compound in a study in patients with major depressive disorder.
A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity disorder, Axsome Therapeutics has unveiled mixed results for the same compound in a study in patients with major depressive disorder.
